Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study [PDF]
Osong Public Health and Research PerspectivesObjectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older.
Dong-Hwi Kim +7 more
doaj +1 more source
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment:a retrospective cohort study [PDF]
BACKGROUND: The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID ...
Birch, Helen J +8 more
core +3 more sources
Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions
Infectious Diseases and TherapyIntroduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of ...
Abby E. Rudolph +5 more
doaj +1 more source
Infection and Drug Resistance, 2023 Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X +8 more
doaj
Paxlovid in Kidney Failure: A Review [PDF]
The COVID-19 virus caused a global pandemic that claimed many lives. Various vaccines and drugs are used for COVID-19 both via intravenous and oral routes.
Ardianty, Nonie +2 more
core +2 more sources
Nature Communications, 2023 Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization.
Robert M. Cox +13 more
doaj +1 more source
A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments [PDF]
Objective: Unusual clinical course Background: SARS-CoV-2 infection can persist in immunocompromised patients with hematological malignancies, despite antiviral treatment.
Cingolani, Antonella +8 more
core +1 more source
Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19. A prospective study [PDF]
COVID-19 represents a threat for frailty patients. This study compares molnupiravir and nirmatrelvir for fragile COVID19 patients' efficacy, safety, and cost.
Cattaruzza, Maria Sofia +6 more
core +1 more source
Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings [PDF]
Introduction: SARS-CoV-2 is now endemic and expected to remain a health threat, with new variants continuing to emerge and the potential for vaccines to become less effective.
Andrew, Melissa +23 more
core +2 more sources
Scientific ReportsNirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain.
Fatemeh Saheb Sharif-Askari +5 more
doaj +1 more source